Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  GlaxoSmithKline Pharmaceuticals Limited    GLAXO   INE159A01016

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote National Stock Exchange O…
02/15/2017 02/16/2017 02/17/2017 02/20/2017 02/21/2017 Date
2698(c) 2662(c) 2693(c) 2673(c) 2700(c) Last
5 123 7 858 4 317 10 633 4 653 Volume
+0.52% -1.33% +1.16% -0.74% +1.01% Change
More quotes
Financials ( INR)
Sales 2017 29 200 M
EBIT 2017 4 157 M
Net income 2017 3 283 M
Finance 2017 8 976 M
Yield 2017 1,97%
Sales 2018 33 081 M
EBIT 2018 6 088 M
Net income 2018 4 590 M
Finance 2018 5 439 M
Yield 2018 2,11%
P/E ratio 2017 70,07
P/E ratio 2018 49,76
EV / Sales2017 7,50x
EV / Sales2018 6,73x
Capitalization 228 097 M
More Financials
Company
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals.The company's product portfolio includes prescription medicines and vaccines.Its prescription medicines range across therapeutic areas such as anti-infective, dermatology,... 
Sector
Pharmaceuticals
Calendar
05/31Earnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline Pharmaceut
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE PHARMACEUT
02/17 GLAXOSMITHKLINE PHARMACEUTICALS : AKD Securities Limited Equity Research - Trigg..
02/16 Vectura Hits GBP9 Million Royalty Cap Under Skyepharma Legacy Deal
02/14 GLAXOSMITHKLINE PHARMACEUTICALS : GSK declares quarterly figures
02/14 GLAXOSMITHKLINE : ViiV Gets Encouraging HIV Treatment Trial Results
02/13 GLAXOSMITHKLINE PHARMACEUTICALS : Pharma Q3 profit dips 33 per cent at Rs 53 cro..
02/13 GLAXOSMITHKLINE PHARMACEUTICALS : Q3 Net Sales declines by 6% with an underlying..
02/09 GLAXOSMITHKLINE PHARMACEUTICALS : Glaxo booster
02/08 GLAXOSMITHKLINE : Glaxo posts 4Q profit
02/08 GLAXOSMITHKLINE : Glaxo 2017 Outlook Dependent On Advair Generic Threat
02/08 TOP NEWS : Glaxo Outlook Depends On Potential Generics, 2016 Revenue Up
More news
Sector news : Pharmaceuticals - NEC
02:05aDJBRISTOL MYERS SQUIBB : Carl Icahn Takes Stake in Bristol-Myers Squibb -- 2nd Upd..
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21 Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
02/21DJBRISTOL MYERS SQUIBB : Carl Icahn Takes Stake in Bristol-Myers Squibb -- Update
02/21DJBRISTOL MYERS SQUIBB : Carl Icahn Takes Stake in Bristol-Myers Squibb -- Sources
More sector news : Pharmaceuticals - NEC
Latest Tweets
2016#Indian #stocks: #Market: Glaxosmithkline Pharmaceuticals : Apr 2016 growth p.. 
2015#Indian #stocks: #Merger #Acquisition: Glaxosmithkline Pharmaceuticals : spar.. 
2015#Indian #stocks: #Market: Glaxosmithkline Pharmaceuticals : Sep 2015 growth p.. 
2015#IndiaBombay #stocks: #Merger #Acquisition: Glaxosmithkline Pharmaceuticals :.. 
2015#Indian #stocks: Glaxosmithkline Pharmaceuticals : #Market Analysts say: good.. 
More tweets
Qtime:6
Advertisement
Chart GLAXOSMITHKLINE PHARMACEUT
Duration : Period :
GlaxoSmithKline Pharmaceut Technical Analysis Chart | GLAXO | INE159A01016 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE P...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 2 753  INR
Spread / Average Target 2,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Deepak Shantilal Parekh Non-Executive Chairman
Andrew Aristidou Chief Financial Officer & Executive Director
Raju Krishnaswamy Executive Director & Technical Director
Vrishali Desai Vice President-Medical & Clinical Research
D. Sundaram Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PHARMA..-2.09%3 388
JOHNSON & JOHNSON3.86%323 362
ROCHE HOLDING LTD.4.90%209 882
PFIZER INC.3.51%204 018
NOVARTIS AG3.51%200 997
MERCK & CO., INC.11.23%180 289
More Results